Price cuts loom on latest pre-AMNOG call up
This article was originally published in Scrip
Executive Summary
Companies like Servier, Johnson & Johnson, and Amgen facing a retrospective AMNOG benefit assessment in Germany would do well to seek advice from the G-BA, the committee in charge of the process, as soon as possible, advises EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs. Such firms will need to know not only what data they need to produce, but also whether they qualify for reduced data requirements, said Matthias Heck, EUCOPE's legal counsel.